Drug Profile
Insulin biosimilar - Julphar
Alternative Names: Julphar Insulin R; Jusline R; Recombinant human insulin - Julphar; Regular insulin human biosimilar - Julphar; Soluble human insulin biosimilar - JulpharLatest Information Update: 21 Jan 2022
Price :
$50
*
At a glance
- Originator Julphar Gulf Pharmaceutical Industries
- Class Antihyperglycaemics; Hepatoprotectants; Insulins; Pancreatic hormones
- Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Diabetes mellitus
Most Recent Events
- 28 Jan 2018 No recent reports of development identified for phase-I development in Diabetes-mellitus in Germany (SC, Injection)